Investor Centre | AFT Pharmaceuticals

Investor Centre >

AFT Pharmaceuticals are a growing multinational pharmaceutical company that develops, markets and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over-the-counter, prescription and hospital.

AFT's product portfolio comprises both proprietary and in-licensed products, and includes patented, branded and generic drugs.
Maxigesic global growth continues

AFT Pharmaceuticals (‘AFT’) has reached agreement with privately-owned Swiss headquartered multinational pharmaceutical company, Acino Pharma AG (‘Acino’), to out-license the product line of its patented combination painkiller, Maxigesic, to a further 69 countries.

To view the announcements please click here.
NZX

Shares in AFT Pharmaceuticals Limited (“AFT”), began trading on the NZX Main Board and ASX on 22 December 2015, following the successful IPO that raised $35.6 million through the issue and sale of New and existing shares.

To view the announcements please click here.

NZX ASX

2.15

0.00 0.0%

8:06AM 24/12/2018

1.98

0.00 0.0%

12:05PM 06/12/2018

NZX ASX

Financial Year End	31/03/2019
Financial Half Year End	30/09/2019
Annual Shareholders Meeting	August 2019
FY2019 Full Year Results Announcement	May 2019
Financial Year End	31/03/2020

Sign up for a request to be invited onto
our email subscribers database.

Subscribe